Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT

@article{Bontant2014SurveyOC,
  title={Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT},
  author={Thomas Bontant and Peter Sedlacek and Adriana Balduzzi and B. Gaspar and Simone Cesaro and Hermann Einsele and Charles Peters and J. Dalle},
  journal={Bone Marrow Transplantation},
  year={2014},
  volume={49},
  pages={276-279}
}
Human CMV infection is a frequent complication after HSC in children with remarkable morbidity and mortality. Antiviral drugs are relatively efficient but have numerous side effects. They are used as prophylactic, pre-emptive or therapeutic medicines. It is still a matter of debate which option is the best strategy. No uniform procedure has emerged regarding these three options, and new immunologic tools have raised more questions for physicians. To assess the current practice in the management… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification (NAT)-Based Assays

  • JF Fryer, AB Heath, R Anderson, PD Minor, Units WHOB, CS Group
  • World Health Organization: Geneva, Switzerland,
  • 2010

Similar Papers

Loading similar papers…